L-3,4-dihydroxyphenylalanine-induced sprouting of serotonin axon terminals: A useful biomarker for dyskinesias?

Annals of Neurology

Volumn 68, Issue 5, 2010, Pages 578-580

  Picconi, Barbara ^a   Ghiglieri, Veronica ^a   Calabresi, Paolo ^b  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE; LEVODOPA; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN 1B AGONIST; SEROTONIN RECEPTOR;

CELL SURVIVAL; DISEASE ACTIVITY; DRUG BINDING; DRUG EFFICACY; DRUG INHIBITION; DYSKINESIA; EDITORIAL; HUMAN; NERVE CELL GROWTH; NERVE ENDING; NEUROTRANSMITTER RELEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SEROTONINERGIC NERVE CELL; SYNAPSE; UPREGULATION;

BIOMARKERS, PHARMACOLOGICAL; DYSKINESIA, DRUG-INDUCED; LEVODOPA; MODELS, NEUROLOGICAL; PRESYNAPTIC TERMINALS; SEROTONIN;

EID: 78249242077     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22231     Document Type: Editorial

References (17)

1. Obeso JA, Olanow CW, Nutt JG., Levodopa motor complications in Parkinson-s disease. Trends Neurosci 2000; 23: S2 - S7.
2. Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson-s disease: current controversies. Mov Disord 2004; 19: 997 - 1005.
3. Olanow CW, Obeso JA., Preventing levodopa-induced dyskinesias. Ann Neurol 2000; 47: S167 - S176.
4. Jankovic J., Motor fluctuations and dyskinesias in Parkinson-s disease: clinical manifestations. Mov Disord 2005; 20: S11 - S16.
5. Rascol O, Goetz C, Koller W, et al. Treatment interventions for Parkinson-s disease: an evidence-based assessment. Lancet 2002; 359: 1589 - 1598.
6. Carta M, Carlsson T, Munoz A, et al. Serotonin-dopamine interaction in the induction and maintenance of L -DOPA-induced dyskinesias. Prog Brain Res 2008; 172: 465 - 478.
7. Carta M, Carlsson T, Kirik D, Bjorklund A., Dopamine released from 5-HT terminals is the cause of L -DOPA-induced dyskinesia in parkinsonian rats. Brain 2007; 130: 1819 - 1833.
8. Kannari K, Yamato H, Shen H, et al. Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L -DOPA in the striatum with nigrostriatal denervation. J Neurochem 2001; 76: 1346 - 1353.
9. Tanaka H, Kannari K, Maeda T, et al. Role of serotonergic neurons in L -DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 1999; 10: 631 - 634.
10. Fox SH, Chuang R, Brotchie JM., Serotonin and Parkinson;s disease: on movement, mood, and madness. Mov Disord 2009; 24: 1255 - 1266.
11. Munoz A, Li Q, Gardoni F, et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L -DOPA-induced dyskinesia. Brain 2008; 131: 3380 - 3394.
12. Rylander D, Parent M, O-sullivan S, et al. Maladaptive plasticity of serotonin axon terminals in L -DOPA-induced dyskinesia. Ann Neurol 2010; 68: 619 - 628.
13. Mamounas LA, Altar CA, Blue ME, et al. BDNF promotes the regenerative sprouting, but not survival, of injured serotonergic axons in the adult rat brain. J Neurosci 2000; 20: 771 - 782.
14. Mattson MP, Maudsley S, Martin B., BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci 2004; 27: 589 - 594.
15. Linazasoro G., New ideas on the origin of L -DOPA-induced dyskinesias: age, genes and neural plasticity. Trends Pharmacol Sci 2005; 26: 391 - 397.
16. Picconi B, Centonze D, Hakansson K, et al. Loss of bidirectional striatal synaptic plasticity in L -DOPA-induced dyskinesia. Nat Neurosci 2003; 6: 501 - 506.
17. Picconi B, Paille V, Ghiglieri V, et al. L -DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Neurobiol Dis 2008; 29: 327 - 335.